Background {#Sec1}
==========

Dengue fever, a mosquito-borne flavivirus infection caused by four related but antigenically distinct dengue viruses (DENVs, serotypes 1--4), is a major and rapidly increasing public health problem. Its geographic range now includes about half of the world's population and continues to expand, with epidemics that disrupt health care systems \[[@CR1]--[@CR4]\]. Current WHO estimates are of about 50--100 million annual infections globally, while Bhatt et al. recently estimated 390 million infections annually with 96 million disease episodes \[[@CR5]--[@CR7]\].

However, there are no other suitable disease prevention methods: mosquito vector control is often ineffective \[[@CR8], [@CR9]\]. There is a vaccine, Sanofi Pasteur's live attenuated Dengvaxia®, recently registered in multiple countries in Southeast Asia and Latin America and it shows to have variable efficacy \[[@CR10]--[@CR13]\]. At present, there are no drugs for specific treatment and there is a need for accurate and cheap dengue diagnostic tests to be widely used in clinical settings \[[@CR14]--[@CR16]\]. Thus, many dengue endemic countries in the tropics are still experiencing a rise in cases and in deaths due to dengue \[[@CR17]--[@CR20]\].

Recently the WHO Strategic Advisory Group of Experts (SAGE) on Immunization emphasized the need for estimation of the true burden of dengue disease, including cost of illness \[[@CR6]\]. Data are available, but mostly focused in countries in Asia and Latin America, with well-documented hyper-endemicity and a long history of dengue transmission, such as Thailand \[[@CR21], [@CR22]\], the Philippines \[[@CR23]\], Brazil \[[@CR24], [@CR25]\], Mexico \[[@CR26]\], and Colombia \[[@CR27]\]. Most of the available burden data are from studies of the epidemiology and evidence based on economic studies is limited \[[@CR28], [@CR29]\].

Among the key limitations of economic studies of dengue are the challenges in its diagnosis. Often, cost-related studies for dengue are based on clinical, rather than laboratory, confirmation \[[@CR30]\]. Available methods include virus isolation, serology, and molecular methods \[[@CR31]\]. One test routinely used by research laboratories for virus identification is Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay \[[@CR32]\]. While this is a definite proof of infection and confirms the serotype, commercial kits that include serotyping are often expensive and would require serum samples collected in early phase during the illness \[[@CR33]\]. Another commonly used method is immunoglobulin type M (IgM) antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) \[[@CR31]\]. With IgM staying elevated for 2 to 3 months, interpretation could be challenging given that elevated IgM could be due either to recent past infection or to cross-reactivity with other flaviviruses \[[@CR33]\]. Any clinical management decision reached on the basis of a single blood sample collected in the acute phase is not conclusive. Levels of immunoglobulin type G (IgG) stay elevated for months to years, so a positive result on one of the available assays could indicate a past infection, thus has limited implications for clinical management \[[@CR31]\]. Moreover, it may cross-react across the Flavivirus group (dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, Zika virus, etc.) \[[@CR34]\]. There are other assays such as Plaque Reduction Neutralization Test (PRNT) which detect serotype-specific antibodies \[[@CR35]\]. Compared to others mentioned, these are time-consuming and labour-intensive, thus expensive \[[@CR36], [@CR37]\].

Amongst different diagnostic tools, rapid diagnostic tests (RDTs) are a convenient (easy to use) and prompt option, despite their limitations in terms of accuracy \[[@CR38]\]. While their availability could be limited, especially in resource-limited settings, RDTs are commonly used for dengue detection in many endemic countries \[[@CR38]\]. There could be a number of different commercially available tests and they could be based on the detection of dengue virus non-structural protein 1 (NS1) antigen, IgM, IgG, and IgA antibodies \[[@CR39]\]. Often, these tests have high specificity (usually around 90%), but lower levels of sensitivity, ranging from 10 to 99%, in detection of dengue and could be cross-reactive with other flaviviruses \[[@CR39]--[@CR42]\]. However, the speed of RDTs provides early diagnosis of dengue possibly leading to timely case management. Given their limited accuracy, these RDTs are not considered the standard reference and their usefulness is not yet proven in clinical settings \[[@CR15], [@CR43]\]. However, some literature supports the use of such tests in combination with others, for example the combined test with NS1 antigen and IgM antibody \[[@CR42], [@CR44]\].

Especially in terms of economic studies, one major benefit of using RDTs would be that they allow dengue detection in the early phase of illness (at presentation), hence facilitating capture of the entire spectrum of costs incurred throughout illness. Previous studies reported that early detection is effective in reducing the duration of illness, possibly leading to lower cost-of-illness due to dengue \[[@CR45], [@CR46]\]. In recognition of the need to balance speed, accuracy, and availability to maximize utility when using RDTs for dengue detection for the patients in clinical settings, a systematic review was performed to explore the economic impact of using RDTs for dengue. The hypothesis behind this review was that there may be economic impact due to prompt detection of dengue in the early phase of illness using RDTs and economic impact is defined to be broad: both from the point of view of cost-effectiveness and from the perspective of financial impact of RDT in patients, i.e. early diagnosis possibly leading to cost-saving in patients.

Methods {#Sec2}
=======

In this review, literature published in English up to September 2017 was covered. Scientific databases used for the search were: Embase, IBSS, Medline (including PubMed), and Web of Science. In order to take more caution and not miss articles that may imply on economic benefit of RDTs, the literature search was conducted in a comprehensive approach. In Pubmed, advance search was performed with search terms "((Dengue\[Title\]) AND cost)" OR "((Dengue\[Title\]) AND economic)" AND:"rapid diagnostic test\[MeSH Terms\]""RDT\[MeSH Terms\]""rapid test\[MeSH Terms\]""rapid assay\[MeSH Terms\]""rapid diagnostic assay\[MeSH Terms\]""point-of-care \[MeSH Terms\]""POC\[MeSH Terms\]""point-of-care test\[MeSH Terms\]"

MeSH terms are assigned by indexers of the National Library of Medicine \[[@CR47]\]. While the search on Pubmed was performed with above search terms with "rapid diagnostic test" and "point-of-care test" were used as MeSH terms, additional articles were identified through IBSS, EMBASE, and Web of Science via general search using keywords:"dengue and rapid diagnostic test (or RDT) and cost""dengue and rapid diagnostic test (or RDT) and economic""dengue and point-of-care (or POC) and cost""dengue and point-of-care (or POC) and economic".

From Embase, Web of Science, and WHOLIS, outcomes of general search included meeting abstracts in addition to full articles. Preliminary screening needed to be done for search outcomes through Embase and Web of Science, as their general search led to journals, not articles, where each key word may appear in different articles.

After such preliminary screening was done for search outcomes through Embase and Web of Science, title screening, abstract review, and full-text review were done. The development of this literature review is shown in the flow chart (Fig. [1](#Fig1){ref-type="fig"}). Rationales for excluding articles obtained through this multiple searches using different sources were described in Fig. [1](#Fig1){ref-type="fig"}. Exclusion criteria were not relevant articles that:mainly report on cost associated with a new diagnostic technologyreport on different technologies or performance of the tests without addressing cost or economic aspect of RDT usereport on RDT-confirmed dengue case numbers in a study with insufficient information on economic impact Fig. 1Flow of the literature search in the systematic review

Also included for full-text review were those describing, in addition to those with direct reporting of quantitative costs, some qualitative economic benefit, i.e. mention of cost-effectiveness of RDTs without any quantitative valuation of it. This was done to prevent loss of any articles containing cost-related implication, even if not quantitatively specified in the article. Data were then extracted from the full texts of the selected articles. The data extraction table was developed following the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement and the reporting Checklist \[[@CR48]\]. Also, the reporting Checklist for Cost-effectiveness Analyses from Second Panel on Cost-Effectiveness in Health and Medicine (Additional file [1](#MOESM1){ref-type="media"}: Table S1) \[[@CR48], [@CR49]\]. In addition, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were followed \[[@CR48], [@CR50]\]. This review is registered in the PROSPERO international prospective register of systematic reviews, under the title "Systematic review of health economic assessments of dengue rapid diagnostic tests" (registry number: CRD42015017775). Full text review was performed independently by two individuals.

Results {#Sec3}
=======

As shown in Fig. [1](#Fig1){ref-type="fig"}, a more focused advanced search on Pubmed resulted in 11 articles and, after preliminary screening of the outcomes of general search on EMBASE and Web of Science, there were 15 published works (2 articles from EMBASE and 14 titles from Web of Science with one in overlap). After removal of duplicative articles, 21 titles from all three sources underwent screening. For abstract review, 10 articles and 2 meeting abstracts were considered relevant and among these 5 articles were selected for full-text review and 1 meeting abstract was retained and, as an abstract, skipped the full-text review step.

On review of the full text of the articles, it was found that only two studies reported quantitative or qualitative economic impact of RDT use for dengue: one by Lubell et al. and another by Mitra et al. The second study was reported in an abstract and an article, the former being published first \[[@CR51], [@CR52]\]. As the abstract was referring to the same study results as the articles, they were merged in the data extraction stage and were presented as one combined piece of work. Some others found with "cost" or "economic" as one of the key search terms and reached the full-text review stage were proven to contain information on the cost aspects of dengue RDTs. However, some were found to report on the actual price of the test or cost of production of a new assay as they assess performance of it. The extracted data and findings from these two studies are included in Additional file [1](#MOESM1){ref-type="media"}: Tables S1, 2a, and 2b \[[@CR51]--[@CR53]\].

The article (2016) and meeting abstract (2014) by Mitra et al. report that Panbio RDT alone is highly sensitive and cost effective for diagnosis of dengue infection in their comparative evaluation of performance and cost-effectiveness of commercially available immunochromatography-based RDT kits \[[@CR51], [@CR52]\]. This study is not, in fact, a cost-effectiveness analysis and reports a high sensitivity (97%) for Panbio RDT and a cost of 13.6 USD (reported in the abstract in 2014, 6.90 USD in the article in 2016) which they refer to as being cost-effective without clearly defining the basis of measurements, i.e. denominator \[[@CR51], [@CR52]\]. They compared four commercially available RDTs \[Panbio Dengue Duo cassette, Standard Diagnostics (SD) Bioline Dengue Duo, J. Mitra Dengue Day-1 test and Reckon Dengue IgG/IgM\] against composite reference criteria (CRC), and compared the cost of the tests. The authors conducted this study among stored blood samples from 281 patients who sought care for acute febrile illness at Christian Medical College (CMC) hospital in Vellore, India \[[@CR52]\]. The CRC was locally developed by infectious diseases expert, virologist, epidemiologist, reflecting WHO guidelines and this was used to identify dengue cases while lab-confirmed etiology of other cases of fever was needed to identify non-dengue controls. The authors measured sensitivity, specificity, and predictive values of these commercial RDTs in dengue cases and non-dengue controls. Based on IgM capture positivity of the four selected RDT kits, Panbio test was found to have the highest sensitivity, followed by SD Duo (97.7 and 64.3% respectively) \[[@CR52]\]. However, specificity was higher for the Reckon RDT and SD Duo at 99.3 and 96.6%, respectively, compared to Panbio at 87.8%. Based on NS1 antigen capture assay, none were found to show satisfactory results in terms of sensitivity, while specificity was high, around 90% \[[@CR52]\]. Therefore, even though the cost of Panbio test was the highest at 6.90 USD (in 2016) compared to the rest three ranging between 3.29 to 4.27 USD, it was concluded that IgM assay by Panbio would be the test of choice and a cost-effective option for diagnosis of acute dengue infection in endemic settings.

An economic evaluation based on cost-effectiveness modeling by Lubell et al. (2016) reported that use of a dengue RDT is found to be not advantageous, more costly and less effective, when compared to the common practice of presumptive treatment with antibiotics prescription \[[@CR53]\]. The authors developed a model to measure the impact and cost-effectiveness of testing for elevated C-reactive protein (CRP), compared with RDTs for dengue and scrub typhus in the management of undifferentiated fever. They used data from 1083 outpatients between 5 and 49 years of age from three provincial hospitals in rural Laos \[[@CR53]\]. A decision tree model was developed to determine cost effectiveness of different testing approaches for undifferentiated fever and measure the ability of dengue and scrub typhus rapid tests, compared with testing for elevated CRP, to inform antibiotic treatment as currently practiced in clinical settings. The authors assumed sensitivity and specificity of a dengue RDT to be 95% and conducted economic evaluation to calculate the median incremental cost, the number of disability adjusted life years (DALYs) averted, and incremental cost-effectiveness ratios (ICER) for each strategy compared to the current practice of antibiotics prescription. For this, the model adopted assumptions in sensitivity and specificity of tests, costs of tests, the cost of a course of antibiotic, duration of all self-limiting viral infections and treated bacterial infection, as well as duration of bacterial infections that do not receive an appropriate treatment, mortality rate, a mean loss of life-years for a case of death, etc. Another important parameter in the model was incidence. The authors used incidence estimates of different pathogens to calculate proportion of patients who were given antibiotics for bacterial infections and proportion of those given antibiotics for viral infections. Furthermore, variable level of incidence between half to double of what was found in the fever study was applied in the model to test robustness of model outcomes. The model output reported that a dengue RDT is dominated by current practice, with a higher cost (median incremental cost = \$1.5, Crl: 0.5; 3.2) and fewer numbers of DALYs averted (−0.006 DALYs, CrI: −0.301; 0.089) on average.

Discussion {#Sec4}
==========

The hypothesis behind this review was that prompt detection of dengue in the early phase of illness using RDTs may lead to economic benefit in terms of patients' cost of illness. The review was from both the point of view of cost effectiveness of RDT and the perspective of financial impact of RDT. We found two studies with different conclusions \[[@CR51]--[@CR53]\]. Two studies were heterogenous in terms of design --- cost-effectiveness modelling or comparative evaluation of performance of RDTs. They both took place in dengue-endemic locations, in India and in Laos, over different time periods between 2008 and 2013 \[[@CR51]--[@CR53]\]. In both studies, the authors acknowledged limited generalizability to other populations of febrile patients, possibly due to specific epidemiological characteristics of each study area \[[@CR51]--[@CR53]\]. Epidemiological profiles, such as a varying level of sero-prevalence and likely high proportion of secondary infections \[[@CR42]\], and particular serotype profiles \[[@CR54], [@CR55]\] could affect performance of RDTs for detection of dengue.

In the comparative evaluation of performance of RDTs, the authors concluded that Panbio RDT is cost-effective. Performance of IgM assay by Panbio was the most satisfactory in the diagnosis of acute dengue infection and the cost of the test was acceptable. This was although the cost based on the manufacturer's quoted price in India for Panbio was the highest at 6.90 USD compared to the rest three: SD, Reckon and J. Mitra at US\$ 4.27, 3.29 and 3.61, respectively. The authors also explored different combinations. When NS1 antigen capture positivity alone was considered, all three tests (Panbio is IgM assay only) showed sensitivity below 30% while specificity was satisfactory, higher than 90% for all three tests. Thus, the authors concluded the NS1-based test to be unreliable. Also, the authors explored changes in performance when combined tests were used. Paired with Panbio RDT, other three RDTs only marginally increased the sensitivity while combination of Reckon with any of the three RDTs was found to increase specificity to higher than 99%. However, such combined testing would double the cost. Thus, the authors concluded that Panbio IgM-based RDT alone would be a cost-effective and sensitive option especially during the times of outbreak in dengue-endemic settings \[[@CR51]\].

The main limitation of the study is that the RDT performance was not compared with other standard tests, such as NS1 or IgM capture based ELISA or RT-PCR. There are standard ways of laboratory-based confirmation of dengue infection using various assays that are available. While the authors indicate that using CRC as case definition is commonly done, such an assessment of RDT performance may not be most accurate. Also, as acknowledged by the authors, the study results could have been affected by cross-reactivity with other flaviviruses circulating in the study area \[[@CR52]\]. Also, dengue RDTs are commonly used especially in the areas of high incidence of dengue \[[@CR56]\]. However, when the study measured prevalence of dengue, the authors found 15.9 to 49.3% of IgG positivity among the samples in the study and it was comparatively lower than prevalence of IgG positivity previously measured by other studies. If prevalence of dengue or other flaviviruses is lower than what was previously estimated, then performance of the RDTs would have been different in cases of low-level transmission of dengue or other flaviviruses.

Based on an economic evaluation using cost-effectiveness modeling, Lubell et al. showed that the a dengue RDT would provide little or no advantage in terms of health outcomes among patients with AFI while resulting in higher costs than current practice of antibiotics prescription \[[@CR53]\]. As well as a dengue RDT, they had also modeled cost-effectiveness of a scrub typhus RDT and CRP test. For these two, the model showed that there are advantages over current practice of antibiotics prescription while cost would increase. There may be limited generalizability of the model outcomes, due to some of specific assumptions used in the model for this particular study sample obtained from Laos. For example, the years of life lost per death was assumed to be 45 years, based on the median age of outpatients and life expectancy in Laos. For the costs of tests, a gamma distribution was applied with a mean of \$1.5, which may be lower than the current price of commonly used RDTs. The study was conducted in an outpatient-sample where dengue was confirmed in about slightly higher than 10% of the patients. While the study explored how the model outcomes would change if the incidence of dengue were to be variable between 50 and 200% of what was found in the fever study in Laos and found out that still CRP test would outperform both RDTs for dengue and scrub typhus, the study does not report how higher incidence of dengue will impact the median incremental cost and median DALYs averted by using dengue RDTs.

Also, the authors acknowledged limitations due to diagnostic uncertainty where multiple pathogens are detected for some patients whereas some others had no identifiable pathogen as the cause of illness. Depending on misclassification due to diagnostic limitations, there may be changes in economic benefit of dengue RDTs. Another limitation of the study was that the model does not consider societal impact of such viral infections where use of dengue RDTs may not be immediately cost-effective, but diagnosis based on dengue RDTs may provide benefit by raising awareness for signs of severe manifestation of illness or alerting health authorities of outbreaks for preventive and control measures, etc.

The authors, qualitatively, report that there would be improvements to current practice of antibiotics prescription whereby a dengue RDT would be used to prevent antibiotics prescribed to patients with viral infections \[[@CR53]\]. Although not measured, there are long-term benefits of vigilant antibiotics prescription where dengue RDTs could be used for non-dengue confirmation to prompt antibiotics prescription, leading to a higher probability of bacterial infections receiving appropriate treatment. If these societal impact and long-term indirect benefits were considered in economic evaluation, dengue RDTs may be associated with higher cost-effectiveness than what was predicted in the current model.

The main assumption behind the topic of this review was the prompt detection of dengue in the early phase of illness using RDTs leading to economic impact, with both perspectives of cost-effectiveness and financial benefit. There are RDTs that detect IgA, IgM or IgG antibodies, as well as NS1 antigen \[[@CR39]\]. Depending on the detection methods, the utility of these RDTs may be quite different and there can be variable performance characteristics. Only the study by Mitra et al. used commercially available RDTs for comparison, and Lubell et al. conducted a modeling analysis using a hypothetical RDT for dengue with 95% sensitivity and specificity in the model assumption. With limited evidence, such comparison among different test methods (or kits) could not be made in this review \[[@CR42], [@CR57]\]. Also, RDT performance could vary depending on factors such as the type of infection (primary vs. secondary infection), the time since onset of illness, and the serotype. It was assumed that the decision to use RDTs and refer to the test result for diagnosis and to guide clinical management would be at discretion of clinicians. Although there were no data reporting such findings, different RDTs' variable range of performance and accuracy could lead to misclassification in terms of dengue diagnosis. And this could affect the test performance and lead to bias by under or over-estimating the economic impact of early detection of dengue. Limited by data availability and lack of assurance on the direction of bias, these factors influencing performance were not considered in this literature review.

With 2.5 billion people at risk, efforts to develop vaccine and other preventive tools continue, but dengue remains a substantial burden to the healthcare system and society in the endemic countries. \[[@CR7], [@CR58]\]. The total annual global cost of dengue illness was estimated at US\$8·9 billion and in a large country like Brazil, it is reported that the estimated cost for dengue for the epidemic season in the societal perspective would reach as high as US\$ 1212 million after adjusting for under-reporting \[[@CR28], [@CR58], [@CR59]\]. In a study reviewing medical costs associated with case management for dengue fever patients in Mexico, real costs for patients, reported to the Secretariat of Health, were US\$33 for outpatients, and US\$491 for inpatients \[[@CR60]\]. How burdensome dengue treatment costs would be to households was shown in a study conducted in Cambodia where survey results were compared in households with dengue positive and the ones with dengue-negative children \[[@CR61]\]. On average, the total cost of lab-confirmed dengue was 31.5 USD and the total cost per hospitalized dengue case was 40.1 USD \[[@CR61]\]. To finance the cost of a febrile illness, 67% of households incurred an average debt of 23.5 USD \[[@CR61]\]. Compared to an average one-week expenditure on food in Cambodia, about 9.5 US dollars per household, the costs of treatment for dengue, whether outpatient or hospitalized, put enormous financial strain on the household \[[@CR61]\].

Given this burden and financial strain placed by dengue on the health system, as well as individuals and households, many of the articles reviewed acknowledge the need for accurate and simple diagnostic assays for infection in resource-limited settings in regions of high dengue endemicity. However, we have found only two studies with different conclusions reached: one concluded that Panbio RDT at 6.90 USD was cost-effective; the other concluded that a dengue RDT is associated with negative DALYs averted while resulting in higher costs than current practice of antibiotics prescription. The two studies differ in design and findings cannot be directly compared. With no additional studies that explicitly estimated the cost-effectiveness of RDTs for dengue other than these two studies, such assessments must await future studies for more conclusive evidence. Likewise, any economic impact of RDT use in clinical settings, for patients, to health systems, and for particular situations such as outbreaks, remains to be assessed. Such work would guide appropriate interventions to improve patient management in resource-limited settings to reduce the burden of dengue.

Conclusions {#Sec5}
===========

Existing studies of dengue RDTs are largely epidemiological and we found two studies which reported quantitative and qualitative economic impact of their use. However, these two studies reported different conclusions and there is a need for new studies to specifically measure economic impact of dengue RDTs. Such studies would yield greater understanding of the benefit of RDTs for dengue and hence could help reduce the costs incurred due to dengue illness.
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AFI

:   Acute febrile illness

CHEERS

:   Consolidated Health Economic Evaluation Reporting Standards

CRP

:   C-reactive protein

DALYs

:   Disability adjusted life years

DENV

:   Dengue virus

ELISA

:   Enzyme-linked immunosorbent assay

ICER

:   Incremental cost-effectiveness ratios

IgM/IgG

:   Immunoglobulin type M and type G

NS1

:   Nonstructural protein 1

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PRNT

:   Plaque Reduction Neutralization Test

RDTs

:   rapid diagnostic tests

RT-PCR

:   Reverse Transcriptase-Polymerase Chain Reaction
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